These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 10933638)

  • 1. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions.
    Vermes A; Guchelaar HJ; Dankert J
    J Antimicrob Chemother; 2000 Aug; 46(2):171-9. PubMed ID: 10933638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics and pharmacodynamics of antifungal drugs in children].
    Jullien V
    Arch Pediatr; 2011 May; 18 Suppl 1():S42-7. PubMed ID: 21596286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal spectrum of itraconazole and treatment of systemic mycoses with old and new antimycotic agents.
    Van Cutsem J
    Chemotherapy; 1992; 38 Suppl 1():3-11. PubMed ID: 1319313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.
    Lyman CA; Walsh TJ
    Drugs; 1992 Jul; 44(1):9-35. PubMed ID: 1379913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of systemic fungal infections: alternatives to itraconazole.
    Herbrecht R; Nivoix Y; Fohrer C; Natarajan-Amé S; Letscher-Bru V
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i39-i48. PubMed ID: 16120633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the treatment of systemic fungal infections.
    Walsh TJ
    Methods Find Exp Clin Pharmacol; 1987 Nov; 9(11):769-78. PubMed ID: 2834615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Commonly used antifungal agents in the treatment of systemic mycoses].
    Berenguer Berenguer J
    Rev Clin Esp; 1995 Oct; 195 Suppl 3():58-65. PubMed ID: 9441308
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antifungal resistance in opportunistic pathogenic fungi (I). Polyenes and fluorocytosine].
    Martínez-Suárez JV; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 1996; 14(6):384-9. PubMed ID: 8756218
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapeutic safety of antimycotics in the treatment of systemic fungal infections].
    Fehér J; Lengyel G
    Orv Hetil; 2003 Aug; 144(34):1677-82. PubMed ID: 14528841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal Agents: Spectrum of Activity, Pharmacology, and Clinical Indications.
    Nett JE; Andes DR
    Infect Dis Clin North Am; 2016 Mar; 30(1):51-83. PubMed ID: 26739608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The activity of systemic antimycotic drug combinations].
    Viudes A; Pemán J; Cantón E; López-Ribot J; Gobernado M
    Rev Esp Quimioter; 2001 Mar; 14(1):30-9. PubMed ID: 11376347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies in the treatment of systemic fungal infections.
    Medoff G; Kobayashi GS
    N Engl J Med; 1980 Jan; 302(3):145-55. PubMed ID: 6985703
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic antifungal drugs.
    Med Lett Drugs Ther; 1996 Feb; 38(967):10-2. PubMed ID: 8559113
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations.
    Smith J; Andes D
    Ther Drug Monit; 2008 Apr; 30(2):167-72. PubMed ID: 18367976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic optimisation of oral antifungal therapy.
    Schäfer-Korting M
    Clin Pharmacokinet; 1993 Oct; 25(4):329-41. PubMed ID: 8261715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the antifungal activity of the pyrimidine analogs flucytosine and carmofur against human-pathogenic dematiaceous fungi.
    Coelho RA; Almeida-Silva F; Figueiredo-Carvalho MHG; Rabello VBS; de Souza GR; Lourenço MCDS; Rodrigues ML; Almeida-Paes R
    Med Mycol; 2024 Mar; 62(4):. PubMed ID: 38533658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice.
    Polak A
    Chemotherapy; 1987; 33(5):381-95. PubMed ID: 2822362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of agents used in the treatment of pulmonary mycoses.
    Borgers M; Vanden Bossche H; Cauwenbergh G
    Clin Chest Med; 1986 Sep; 7(3):439-52. PubMed ID: 3021382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antifungals for systemic use].
    Ruiz-Camps I; Cuenca-Estrella M
    Enferm Infecc Microbiol Clin; 2009 Jun; 27(6):353-62. PubMed ID: 19482382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.